Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice

Infection and Immunity

Volumn 73, Issue 9, 2005, Pages 5842-5852

  Iborra, Salvador ^a   Carrión, Javier ^a   Anderson, Charles ^b   Alonso, Carlos ^a   Sacks, David ^b   Soto, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC RIBOSOMAL PROTEIN P0; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INFECTION SENSITIVITY; INOCULATION; INTERFERON PRODUCTION; LEISHMANIA INFANTUM; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; CPG ISLANDS; CYTOKINES; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOPROTEINS; PROTOZOAN VACCINES; RIBOSOMAL PROTEINS; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

EID: 23944486753     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.9.5842-5852.2005     Document Type: Article

References (35)

1. Belkaid, Y., S. Kamhawi, G. Modi, J. Valenzuela, N. Noben-Trauth, E. Rowton, J. Ribeiro, and D. L. Sacks. 1998. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva pre-exposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 188:1941-1953.
2. Belkaid, Y., E. Von Stebut, S. Mendez, R. Lira, E. Caler, S. Bertholet, M. C. Udey, and D. Sacks. 2002. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168:3992-4000.
3. Buffet, P. A., A. Sulahian, Y. J. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39:2167-2168.
4. Cho, H. J., K. Takabayashi, P. M. Cheng, M. D. Nguyen, M. Corr, S. Tuck, and E. Raz. 2000. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18:509-514.
5. Coffman, R. L. 1993. Mechanisms of helper T-cell regulation of B-cell activity. Ann. N. Y. Acad. Sci. 681:25-28.
6. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis, current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
7. Datta, N., S. Mukherjee, L. Das, and P. K. Das. 2003. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation. Eur. J. Immunol. 33:1508-1518.
8. Davila, E., and E. Celis. 2000. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol. 165:539-547.
9. Greenblatt, C. L. 1980. The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 47:259-285.
10. Gumy, A., J. A. Louis, and P. Launois. 2004. The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int. J. Parasitol. 34:433-444.
11. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
12. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:229-243.
13. Hartmann, G., G. J. Weiner, and A. M. Krieg. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305-9310.
14. Hashemi-Fesharki, R., S. Alle-Agha, P. Ahourai, E. Djavadian, A. Taghavi, A. Golabi, M. Kamail, K. Esmail-Nia, H. Ghafari, F. Mofasali, and R. Kheirol-Omour. 1992. Vaccine preparation and quality control of killed Leishmania major. Arch. Inst. Razi 43:39-50.
15. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505-1509.
16. Iborra, S., M. Soto, J. Carrion, A. Nieto, E. Fernandez, C. Alonso, and J. M. Requena. 2003. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect. Immun. 71:6562-6572.
17. Kellina, O. I. 1981. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R. Bull. Soc. Pathol. Exot. Filiales 74:306-318.
18. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93:2879-2883.
19. Mendez, S., Y. Belkaid, R. A. Seder, and D. Sacks. 2002. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine 20:3702-3708
20. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
21. Mendez, S., K. Tabbara, Y. Belkaid, S. Bertholet, D. Verthelyi, D. Klinman, R. A. Seder, and D. L. Sacks. 2003. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect. Immun. 71:5121-5129.
22. Molano, I., M. G. Alonso, C. Miron, E. Redondo, J. M. Requena, M. Soto, C. G. Nieto, and C. Alonso. 2003. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet. Immunol. Immunopathol. 92:1-13.
23. Nadim, A., E. Javadian, G. Tahvildar-Bidruni, and M. Ghorbani. 1983. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. Filiales 76:377-383.
24. Requena, J. M., S. Iborra, J. Carrion, C. Alonso, and M. Soto. 2004. Recent advances in vaccines for leishmaniasis. Expert Opin. Biol. Ther. 4:1505-1517.
25. + T cell responses and protection against Leishmania major infection. J. Exp. Med. 195:1565-1573.
26. Sacks, D., and C. Anderson. 2004. Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol. Rev. 201:225-238.
27. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-858.
28. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171:115-127.
29. Scott, P., D. Artis, J. Uzonna, and C. Zaph. 2004. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol. Rev. 201:318-338.
30. Sjolander, A., T. M. Baldwin, J. M. Curtis, and E. Handman. 1998. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:3949-3957.
31. Skeiky, Y. A., D. R. Benson, M. Elwasila, R. Badaro, J. M. Burns, Jr., and S. G. Reed. 1994. Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins. Infect. Immun. 62:1643-1651.
32. Soto, M., J. M. Requena, L. Quijada, F. Guzman, M. E. Patarroyo, and C. Alonso. 1995. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Immunol. Lett. 48:23-28.
33. Sparwasser, T., and G. B. Lipford. 2000. Consequences of bacterial CpG DNA-driven activation of antigen-presenting cells. Curr. Top. Microbiol. Immunol. 247:59-75.
34. Sparwasser, T., R. M. Vabulas, B. Villmow, G. B. Lipford, and H. Wagner. 2000. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 30:3591-3597.
35. Zimmermann, S., O. Egeter, S. Hausmann, G. B. Lipford, M. Rocken, H. Wagner, and K. Heeg. 1998. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160:3627-3630.